Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Shares Outstanding (Diluted Average) (2018 - 2025)

Denali Therapeutics (DNLI) has disclosed Shares Outstanding (Diluted Average) for 8 consecutive years, with $172.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 4.97% to $172.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $172.6 million through Dec 2025, up 4.97% year-over-year, with the annual reading at $172.6 million for FY2025, 4.97% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $172.6 million at Denali Therapeutics, roughly flat from $172.4 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $172.6 million in Q4 2025, with the low at $120.9 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $143.6 million, with a median of $137.5 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) rose 1.08% in 2022, then increased 23.11% in 2024.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $121.5 million in 2021, then grew by 3.3% to $125.5 million in 2022, then increased by 9.43% to $137.4 million in 2023, then grew by 19.73% to $164.5 million in 2024, then increased by 4.97% to $172.6 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $172.6 million, $172.4 million, and $171.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.